Latest News
European Commission approves Novartis' Cosentyx for polymyalgia rheumatica
21 October 2026 - Swiss pharmaceutical company Novartis AG (SIX: NOVN; NYSE: NVS) on Wednesday said the European Commission has approved Cosentyx (secukinumab) for adults with polymyalgia rheumatica (PMR) who have had an inadequate response to glucoc...
Edwards Lifesciences wins FDA approval for PASCAL Precision tricuspid repair system
21 October 2026 - Edwards Lifesciences Corporation (NYSE: EW), a structural heart innovation company, announced on Wednesday that it has received US Food and Drug Administration (FDA) approval for its PASCAL Precision system to repair the tricuspid v...
Five-year US study highlights long-term effectiveness of ViiV Healthcare's Cabenuva
21 October 2026 - Specialist HIV company ViiV Healthcare, majority owned by GSK (LON:GSK), with Shionogi as a shareholder, on Wednesday reported five-year real-world data from the US OPERA observational cohort showing sustained viral suppression and ...
GSK wins US FDA approval for chronic hepatitis B treatment Hibsago
21 October 2026 - GSK plc (LSE: GSK) (NYSE: GSK) has received US Food and Drug Administration approval for Hibsago (bepirovirsen), a first-in-class antisense oligonucleotide for treating chronic hepatitis B in eligible adults alongside existing antiv...
Summit Therapeutics and ECOG-ACRIN launch Phase II/III trial collaboration for biliary tract cancer
21 October 2026 - Biopharmaceutical oncology company Summit Therapeutics Inc (NASDAQ:SMMT) said on Wednesday that it has partnered with the ECOG-ACRIN Cancer Research Group to evaluate ivonescimab in a registration-enabling Phase II/III clinical tria...